Renal Thrombotic Microangiopathy Associated with the Use of Bortezomib in a Patient with Multiple Myeloma.
Bortezomib is a first-generation proteasome inhibitor used in the treatment of multiple myeloma (MM). A few reports have linked bortezomib exposure with the development of thrombotic microangiopathy (TMA). We describe a case of biopsy-proven renal thrombotic microangiopathy associated with the use of bortezomib in a 51-year-old man with IgG lambda MM. To our knowledge, this is the first biopsy-proven case. In addition, reexposure to bortezomib 18 months later was associated with recurrence of TMA. This supports a possible causal role of bortezomib. The exact mechanisms remain to be elucidated.
Cardiology, University Hospitals Leuven, Herestraat 49, 3000 Leuven, Belgium.
Jan
J
Van Keer
Hematology, University Hospitals Leuven, Herestraat 49, 3000 Leuven, Belgium.
Michel
M
Delforge
Hematology, University Hospitals Leuven, Herestraat 49, 3000 Leuven, Belgium.
Daan
D
Dierickx
Vascular Medicine and Hemostasis, University Hospitals Leuven, Herestraat 49, 3000 Leuven, Belgium.
Kathelijne
K
Peerlinck
Pathology, University Hospitals Leuven, Herestraat 49, 3000 Leuven, Belgium.
Evelyne
E
Lerut
Nephrology, University Hospitals Leuven, Herestraat 49, 3000 Leuven, Belgium.
Ben
B
Sprangers